Bruno Sangro
#128,027
Most Influential Person Now
Researcher
Bruno Sangro's AcademicInfluence.com Rankings
Bruno Sangrocomputer-science Degrees
Computer Science
#5485
World Rank
#5793
Historical Rank
Artificial Intelligence
#1714
World Rank
#1746
Historical Rank
Database
#2638
World Rank
#2760
Historical Rank

Download Badge
Computer Science
Why Is Bruno Sangro Influential?
(Suggest an Edit or Addition)Bruno Sangro's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (2017) (2764)
- Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. (2015) (1463)
- Hepatocellular carcinoma (2016) (1162)
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. (2016) (878)
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (2013) (798)
- Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation (2011) (573)
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) (554)
- CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) (2019) (535)
- BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update (2021) (499)
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. (2011) (490)
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (2020) (433)
- Immunological landscape and immunotherapy of hepatocellular carcinoma (2015) (425)
- New therapies for hepatocellular carcinoma (2006) (388)
- Liver disease induced by radioembolization of liver tumors (2008) (332)
- Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. (2004) (307)
- Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. (2003) (290)
- Radioembolization for hepatocellular carcinoma. (2012) (283)
- Advances in immunotherapy for hepatocellular carcinoma (2021) (277)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (263)
- Prognostic factors and prevention of radioembolization‐induced liver disease (2013) (241)
- Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. (2009) (237)
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (2021) (230)
- Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. (2015) (219)
- Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. (2005) (211)
- Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. (2012) (208)
- Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. (2006) (204)
- Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. (2019) (191)
- Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom (1996) (191)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2019) (187)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (185)
- Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. (2005) (185)
- A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. (2003) (180)
- Research reporting standards for radioembolization of hepatic malignancies. (2011) (180)
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (180)
- Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma (2001) (178)
- Transjugular intrahepatic portal‐systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters (1995) (173)
- Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes (2017) (169)
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma (2020) (167)
- Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. (2017) (159)
- Partial splenic embolization for the treatment of hypersplenism in cirrhosis (1993) (156)
- Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives (2013) (153)
- De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival (2005) (149)
- Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation (2012) (147)
- Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade (2016) (141)
- The Role of Thrombopoietin in the Thrombocytopenia of Patients with Liver Cirrhosis (2005) (137)
- Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. (2010) (136)
- Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas (1999) (136)
- Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90 (2013) (135)
- Hepatitis B and C viral infections in patients with hepatocellular carcinoma (1992) (132)
- Liver transplantation in patients with hepatocellular carcinoma across Milan criteria (2008) (131)
- Targets for immunotherapy of liver cancer. (2017) (131)
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022) (130)
- Systemic treatment of hepatocellular carcinoma. An EASL position paper. (2021) (128)
- Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution (2016) (128)
- Gastroduodenal Injury After Radioembolization of Hepatic Tumors (2007) (126)
- Radioembolization for the Treatment of Liver Tumors: General Principles (2012) (122)
- Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. (1999) (122)
- Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma (2015) (122)
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
- Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8 (2005) (116)
- The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality (2021) (114)
- Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. (2016) (114)
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. (2020) (113)
- Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. (2012) (112)
- Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy (2003) (110)
- Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. (2001) (109)
- A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma (2010) (109)
- Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 (2001) (97)
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (2022) (96)
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (2020) (95)
- Radioembolization for Hepatocellular Carcinoma: A Review of the Evidence and Treatment Recommendations (2011) (95)
- Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model (2013) (94)
- Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal (2011) (87)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (87)
- Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. (1997) (87)
- Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. (2004) (86)
- Gene therapy of cancer based on interleukin 12. (2005) (86)
- Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. (2005) (86)
- Totally Laparoscopic Right‐Lobe Hepatectomy for Adult Living Donor Liver Transplantation: Useful Strategies to Enhance Safety (2013) (86)
- Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis (2019) (85)
- Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. (2013) (85)
- Biocompatibility, Inflammatory Response, and Recannalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings (2009) (83)
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. (2019) (83)
- No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. (2012) (82)
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
- Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance (2013) (80)
- Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review (2017) (80)
- A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. (2018) (79)
- Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC (2015) (78)
- Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model (2018) (78)
- CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. (2021) (76)
- Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. (2017) (76)
- International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres (2021) (76)
- Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (75)
- Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach (2019) (75)
- Nonmelanoma skin cancer after liver transplantation. Study of risk factors (2005) (73)
- Medical treatment for cholangiocarcinoma (2019) (72)
- Color Doppler-US guidance in transjugular placement of intrahepatic portosystemic shunts. (1992) (72)
- Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. (2011) (71)
- Transarterial Chemoembolization and Radioembolization (2014) (70)
- The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. (2017) (69)
- General Selection Criteria of Patients for Radioembolization of Liver Tumors: An International Working Group Report (2011) (69)
- Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. (2014) (67)
- Spontaneous regression of hepatocellular carcinoma: a systematic review (2009) (66)
- Herpes zoster after liver transplantation: Incidence, risk factors, and complications (2004) (64)
- A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. (2016) (64)
- Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages (2011) (60)
- Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients (2011) (60)
- Transarterial therapies for hepatocellular carcinoma (2011) (60)
- Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. (2008) (59)
- Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. (2002) (59)
- Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. (2010) (59)
- A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. (2009) (58)
- Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion (2017) (57)
- Safety and Efficacy Assessment of Flow Redistribution by Occlusion of Intrahepatic Vessels Prior to Radioembolization in the Treatment of Liver Tumors (2010) (57)
- Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events (2018) (56)
- Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. (2019) (56)
- Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. (2009) (54)
- Plasma levels of substance p in liver cirrhosis: Relationship to the activation of vasopressor systems and urinary sodium excretion (1995) (54)
- Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. (2010) (54)
- Spontaneous Regression of Hepatocellular Carcinoma: Three Case Reports and a Categorized Review of the Literature (2009) (53)
- Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report (2009) (51)
- A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib (2016) (51)
- Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. (1998) (50)
- Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation (2015) (50)
- Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12 (2001) (50)
- Liver changes in patients with hyperthyroidism. (2008) (48)
- Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival, and adverse events (2001) (47)
- Totally Laparoscopic Right Hepatectomy for Living Donor Liver Transplantation: Analysis of a Preliminary Experience on 5 Consecutive Cases (2017) (45)
- Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. (2018) (45)
- Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib (2012) (44)
- Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. (2003) (43)
- Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells (2018) (43)
- Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity (2014) (42)
- Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers (2012) (41)
- The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres (2017) (40)
- Gene therapy of liver cancer. (2006) (40)
- Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study. (2016) (40)
- [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. (2016) (40)
- Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies (2002) (40)
- Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins (2019) (40)
- Liver damage using suicide genes. A model for oval cell activation. (2000) (38)
- Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis (2020) (38)
- The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort (2018) (38)
- Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib (2017) (37)
- Prognostic model for early acute rejection after liver transplantation (2001) (37)
- Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials (2018) (37)
- The promise of gene therapy in gastrointestinal and liver diseases (2003) (37)
- Efficacy of transjugular intrahepatic portosystemic shunt to prevent total portal vein thrombosis in cirrhotic patients awaiting for liver transplantation. (2012) (37)
- Treatment of Hepatocellular Carcinoma by Radioembolization Using 90Y Microspheres (2009) (36)
- Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study. (2016) (35)
- Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field. (2002) (33)
- Efficacy and Toxicity of Intra-Arterial Cisplatin and Etoposide for Advanced Hepatocellular Carcinoma (2002) (33)
- The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis (2019) (33)
- Milestones in the pathogenesis and management of primary liver cancer. (2020) (33)
- Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. (2004) (32)
- LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (2020) (32)
- Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. (2017) (32)
- Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver (2012) (31)
- Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. (2020) (31)
- Liver cancer arterial perfusion modelling and CFD boundary conditions methodology: a case study of the haemodynamics of a patient‐specific hepatic artery in literature‐based healthy and tumour‐bearing liver scenarios (2016) (29)
- [Diagnosis of small hepatocellular carcinoma]. (2007) (29)
- Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) (2020) (29)
- Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040. (2021) (28)
- Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells (2017) (28)
- Gene therapy of liver diseases (2004) (28)
- Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. (2017) (28)
- Assessing the impact of COVID-19 on liver cancer management (CERO-19) (2021) (28)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma (2021) (27)
- Risk factors for recurrence of hepatitis C after liver transplantation. (1998) (27)
- Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach (2020) (26)
- Identification of coding and long non-coding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues. (2019) (25)
- Chemoembolization and radioembolization. (2014) (25)
- Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. (2017) (24)
- Hyperhomocysteinemia in liver transplant recipients: Prevalence and multivariate analysis of predisposing factors (2000) (24)
- CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (24)
- A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma (2011) (23)
- Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. (2003) (23)
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. (2020) (23)
- Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors: Introduction to the International Working Group Report (2012) (22)
- Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. (2013) (21)
- Assessment of the Hong Kong Liver Cancer Staging System in Europe (2016) (21)
- Gene Therapy of Hepatocellular Carcinoma and Gastrointestinal Tumors (2002) (21)
- Factors related to increased resting energy expenditure in men with liver cirrhosis (2015) (21)
- P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1 (2020) (20)
- Effectiveness of aprotinin in orthotopic liver transplantation. (1993) (20)
- Computational particle–haemodynamics analysis of liver radioembolization pretreatment as an actual treatment surrogate (2017) (20)
- Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases (2012) (19)
- Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. (1986) (19)
- Gene therapy for liver cancer: clinical experience and future prospects. (2010) (19)
- Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. (2013) (19)
- Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? (2009) (19)
- Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients. (2017) (19)
- Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures (2021) (19)
- The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma (2021) (18)
- Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo (2011) (18)
- Gene therapy of neoplastic liver diseases. (2003) (18)
- Partial splenic embolization in the treatment of thrombocytopenia after liver transplantation. (1997) (18)
- Agenesis of the dorsal pancreas: systematic review of a clinical challenge. (2016) (18)
- NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma (2017) (18)
- Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma (2021) (17)
- Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection (2015) (17)
- Immune monitoring of immunosuppression withdrawal of liver transplant recipients. (2015) (17)
- Renal biopsy with forceps through the femoral vein. (1995) (17)
- Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. (2017) (17)
- Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma (2022) (16)
- Radioembolization for Hepatocellular Carcinoma: Evidence-Based Answers to Frequently Asked Questions (2011) (16)
- The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer (2016) (16)
- Phase I/II multicenter trial of a novel therapeutic cancer vaccine, HepaVac-101, for hepatocellular carcinoma. (2022) (15)
- Computational assessment of the effects of the catheter type on particle-hemodynamics during liver radioembolization. (2016) (15)
- Increased liver stiffness values in patients with heart failure. (2013) (15)
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. (2020) (15)
- Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial (final report Maag Lever Darm Stichting projectno. WS 00???78 (WS 97/87)) (2006) (14)
- The role of angled‐tip microcatheter and microsphere injection velocity in liver radioembolization: A computational particle–hemodynamics study (2017) (14)
- Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma (2020) (14)
- Liver transplantation in cirrhotic patients over 60 years of age. (1998) (14)
- Tumour recurrence after Interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumour growth (2017) (14)
- Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. (2018) (14)
- Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. (2011) (14)
- Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK (2015) (13)
- Subsequent nonmelanoma skin cancer after liver transplantation. (2012) (13)
- Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies (2018) (13)
- Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial (2012) (13)
- Gene Therapy of Hepatocellular Carcinoma (2002) (13)
- Nonsurgical Treatment for Localized Hepatocellular Carcinoma (2014) (13)
- Cancer Immunotherapy Principles and Practice (2018) (13)
- A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization (2021) (12)
- [Comparison of the M and XL FibroScan(®) probes to estimate liver stiffness by transient elastography]. (2014) (12)
- The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis (2020) (12)
- The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective (2021) (12)
- Numerical investigation of liver radioembolization via computational particle-hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. (2016) (12)
- The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. (2020) (12)
- Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma (2020) (12)
- New strategies to enhance gene therapy efficiency. (2002) (12)
- Other clinical studyTransjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters☆ (1995) (12)
- International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis (2020) (12)
- Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. (2001) (12)
- Increased concentrations of tumor necrosis factor and interleukin-6 contribute to the hemostatic abnormalities in advanced liver disease. (1995) (11)
- Refined tools for the treatment of hepatocellular carcinoma. (2005) (11)
- Numerical zero‐dimensional hepatic artery hemodynamics model for balloon‐occluded transarterial chemoembolization (2018) (11)
- Future therapies for hepatocellular carcinoma. (2005) (10)
- Ribavirin in desquamative interstitial pneumonia. (1988) (10)
- Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040 (2017) (10)
- Physiological outflow boundary conditions methodology for small arteries with multiple outlets: A patient-specific hepatic artery haemodynamics case study (2015) (10)
- Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France (2020) (10)
- Biologic therapy of liver tumors. (2004) (9)
- Nivolumab in sorafenib-naive and - experienced patients with advanced hepatocellular carcinoma (HCC): checkMate 040 study (2017) (9)
- Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel (2017) (9)
- A phase I clinical trial of intratumoral injection of adenovirus encoding interleukin-12 in patients with hepatocellular carcinoma and other advanced gastrointestinal tumors (2003) (9)
- Liver Radioembolization Using 90Y Resin Microspheres in Elderly Patients: Tolerance and Outcome (2010) (9)
- Neoantigens as potential vaccines in hepatocellular carcinoma (2022) (9)
- Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. (1998) (9)
- Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. (2021) (9)
- Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. (2017) (9)
- Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial (2021) (9)
- Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study (2018) (9)
- Evaluation of the rabbit liver by direct portography and contrast-enhanced computed tomography: anatomical variations of the portal system and hepatic volume quantification (2017) (9)
- Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. (2021) (9)
- Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC). (2016) (8)
- CONVERSION FROM CYCLOSPORINE A TO MYCOPHENOLATE MOFETIL IN LIVER TRANSPLANT RECIPIENTS WITH RENAL FUNCTION IMPAIRMENT (1998) (8)
- Splicing Factor SLU7 Prevents Oxidative Stress‐Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage (2021) (8)
- O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENING (2014) (8)
- Gene therapy of liver cancer. (2006) (8)
- Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma (2019) (8)
- Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study (2017) (8)
- A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts). (2019) (7)
- Whole body 18fluoro-l-dopa PET–CT: a useful tool for location and surgical guidance in primary carcinoid tumours (2008) (7)
- [Fatal pulmonary embolism after embolization of a hepatocellular carcinoma using microspheres]. (2008) (7)
- Hepatic Flow Redistribution is Feasible in Patients with Hepatic Malignancies Undergoing Same-Day Work-Up Angiography and Yttrium-90 Microsphere Radioembolization (2019) (7)
- Felty's syndrome: Response to cyclosporin A with disappearance of neutrophil autoantiboidies (1991) (7)
- [Treatment of chronic hepatitis B virus infection]. (2004) (7)
- Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage (2018) (7)
- A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). (2021) (7)
- 114 SIRTACE: A RANDOMISED MULTICENTRE PILOT TRIAL OF SELECTIVE INTERNAL RADIOEMBOLISATION (SIRT) WITH YTTRIUM-90 MICROSPHERES VERSUS TRANSARTERIAL CHEMO-EMBOLISATION (TACE) IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) (2013) (7)
- Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres". (2013) (7)
- Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040 (2020) (6)
- Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives (2013) (6)
- 3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization (2021) (6)
- Durvalumab as a Successful Downstaging Therapy for Liver Transplantation in Hepatocellular Carcinoma: the Importance of a Wash-Out Period. (2021) (6)
- Radioembolization-Induced Liver Disease (2013) (6)
- O138 PHASE 1 CLINICAL TRIAL OF LIVER DIRECTED GENE THERAPY WITH rAAV5-PBGD IN ACUTE INTERMITTENT PORPHYRIA: PRELIMINARY SAFETY DATA (2014) (6)
- Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (2020) (6)
- [Spontaneous tumor regression. Report of 2 cases]. (1990) (6)
- Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis. (1992) (6)
- Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. (2022) (6)
- Hepatitis C virus (HCV) viremia in patients with hepatocellular carcinoma (HCC) detected by nested-PCR (1991) (6)
- The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT (2020) (6)
- O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma (2020) (5)
- Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. (2013) (5)
- Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma. (2011) (5)
- [Survival benefit with intraarterial techniques in hepatocellular carcinoma]. (2014) (5)
- [Diagnosis and treatment of hepatocellular carcinoma]. (2009) (5)
- Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (5)
- Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy (2020) (5)
- Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure (2013) (5)
- Transvenous liver biopsy in patients with cirrhosis with use of the femoral venous approach and a flexible forceps. (1994) (5)
- P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073 (2021) (5)
- Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth (2021) (5)
- The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort. (2018) (5)
- European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres. (2010) (5)
- Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma (2018) (4)
- FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040 (2019) (4)
- 1134. Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients with Metastatic Gastrointestinal Carcinomas (2005) (4)
- Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH (2021) (4)
- Immunotherapy of hepatocellular carcinoma. (2014) (4)
- Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib (2022) (4)
- CFD Simulations of Radioembolization: A Proof-of-Concept Study on the Impact of the Hepatic Artery Tree Truncation (2021) (4)
- In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID-19 vaccine-related hepatitis (2022) (4)
- Laparotomic eventration or colonic prolapse after chemotherapy‐induced emesis (1988) (4)
- 268 SAFETY AND TOXICITY OF THE COMBINATION OF Y90-RADIOEMBOLIZATION AND SORAFENIB IN ADVANCED HCC: AN INTERIM ANALYSIS OF THE EUROPEAN MULTICENTER TRIAL SORAMIC (2013) (4)
- Computational Fluid Dynamics Modeling of Liver Radioembolization: A Review (2021) (4)
- A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy (2021) (4)
- Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization (2021) (4)
- Dosimetry and Dose Calculation (2013) (4)
- A methodology for numerically analysing the hepatic artery haemodynamics during B-TACE: a proof of concept (2019) (4)
- Tumors of the Liver and Biliary Tract (1992) (3)
- Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (3)
- Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group (2022) (3)
- 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study (2016) (3)
- [Severe hepatotoxicity caused by amiodarone: description of a case]. (1999) (3)
- SIRT Approval for Early HCC, What Comes Next? (2021) (3)
- New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming (2022) (3)
- Radioembolization for hepatocellular carcinoma: gaining insight on a personalized approach (2017) (3)
- Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells (2020) (3)
- Results in Hepatocellular Carcinoma (2013) (3)
- Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040 (2019) (3)
- Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors (2018) (3)
- Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer. (1987) (3)
- A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. (2020) (3)
- Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience (2018) (3)
- Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial (2021) (3)
- Aortic valve replacement with bioprostheses in liver transplant recipients. (2000) (3)
- Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (3)
- Pneumatocele during sorafenib therapy: first report of an unusual complication (2017) (3)
- Results of two Controlled Studies on Antiemetic Combination against Vomiting Induced by 5-Fluorouracil (1987) (3)
- Selective internal radiation therapy (SIRT) using Y90 resin microspheres as consolidation treatment for liver metastases from colorectal cancer (LCRC). (2015) (3)
- Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood (2022) (3)
- Assessment of liver dysfunction in hepatocellular carcinoma (HCC): An international collaborative study. (2014) (2)
- P1318 : Phase I dose escalation study of the safety, immunoregulatory activity, pharmacokinetics, and preliminary antitumor activity of nivolumab in advanced hepatocellular carcinoma in patients with or without chronic viral hepatitis (2015) (2)
- A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits (2022) (2)
- The ENRY analysis: a 325-patient European multicentre analysis (2012) (2)
- The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation (2021) (2)
- A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC (2020) (2)
- On the importance of spiral‐flow inflow boundary conditions when using idealized artery geometries in the analysis of liver radioembolization: A parametric study (2020) (2)
- Older age and liver transplantation (2005) (2)
- Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study. (2017) (2)
- SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 (2022) (2)
- Radioembolisation — A New Treatment for Primary and Secondary Liver Tumours (2006) (2)
- Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next? (2021) (2)
- 650 SURVIVAL AND TOLERABILITY FOLLOWING Y-RESIN MICROSPHERE RADIOEMBOLISATION IN PATIENTS WITH UNRESECTABLE BCLC STAGE C HEPATOCELLULAR CARCINOMA (HCC) (2011) (2)
- The joint use of 99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning (2021) (2)
- Segmental Pneumonitis after Radioembolization. (2018) (2)
- Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): the CheckMate 040 Study (2016) (2)
- Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study (2016) (2)
- Adenovirus-mediated transfer of suicide gene under control of tumor-specific promoter provides an efficient and safe vector for gene therapy of hepatocellular carcinoma (HCC) (2001) (2)
- 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2022) (2)
- P979 NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A PREDICTOR OF ONE-YEAR SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB (2014) (2)
- Pneumatosis coli due to pharmacological constipation. (2007) (2)
- 795 PROGNOSTIC FACTORS AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) TREATED BY Y90-RADIOEMBOLIZATION (Y90-RE) (2009) (2)
- The Post-Sir-Spheres Surgery Study (P4s): Liver Surgery Can Be Safely Performed In Patients With Hepatocellular Carcinoma (Hcc) Previously Treated with Selective Internal Radiation Therapy (Sirt) using Y-90 Resin Microspheres (2015) (2)
- Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study (2022) (2)
- Sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma (HCC) (SORAMIC). (2012) (2)
- Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial (2022) (2)
- Radioembolisation in Hepatocellular Carcinoma: Principles of Management (2018) (2)
- Liver function considerations for post-selective internal radiation therapy resection (hepatocellular carcinoma and metastatic colorectal cancer). (2014) (2)
- Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections. (2021) (2)
- [In vivo evaluation of gene transfer]. (2002) (2)
- 80 EUROPEAN NETWORK ON RADIOEMBOLISATION WITH 90Y-RESIN MICROSPHERES (ENRY) MULTICENTRE EVALUATION OF SURVIVAL, SAFETY AND LIVER FUNCTION FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) (2011) (2)
- Assessment of radioembolization among patients who met the inclusion criteria for Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP). (2012) (2)
- Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know (2019) (2)
- The role of thrombopoietin on the pathogenesis of thrombocytopenia in liver cirrhosis (2003) (2)
- The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors in a murine hepatocellular carcinoma model (2018) (2)
- Radioembolization: Concepts and Procedures (2013) (2)
- Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines (2012) (2)
- P0118 : Phase 1–2 clinical trial in patients with decompensated liver cirrhosis treated with bone-marrow derived endothelial progenitor cells (2015) (2)
- Gene therapy of primary and metastatic liver tumors. (2001) (1)
- Radioembolization as an adjunct therapy to the resection of liver tumors. (2015) (1)
- Treatment of hepatocellular carcinoma (HCC) with intraarterial combination chemotherapy (1991) (1)
- Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. (2022) (1)
- The post-SIR-Spheres surgery study (P4S): analysis of outcomes following hepatic resection of patients previously treated with selective internal radiation therapy (SIRT), with or without exposure to future liver remnant (FLR) (2015) (1)
- Yttrium-90 Microspheres for Other Liver Metastases (2013) (1)
- Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience (2023) (1)
- Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes (2022) (1)
- 67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) (2022) (1)
- Real-world outcomes of patients with intrahepatic cholangiocarcinoma treated with trans-arterial radioembolization: Results from the CIRSE Registry for SIR-Spheres Therapy (CIRT), a large European prospective multi-center observational study. (2021) (1)
- From the Editor's Desk…. (2021) (1)
- 134 Incidence and mortality of De Novo neoplasia after liver transplantation (LT). Case-control study (2004) (1)
- Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis (2020) (1)
- Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC (2017) (1)
- SLU7 prevents oxidative stress-mediated HNF4 degradation preserving hepatic differentiation and protecting from liver damage (2021) (1)
- Felty's syndrome: response to cyclosporin A with disappearance of neutrophil autoantibodies. (1991) (1)
- Immunotherapy in hepatocellular carcinoma. (2022) (1)
- 189 EFFICACY OF TIPS FOR THE PREVENTION OF TOTAL PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS WAITING FOR LIVER TRANSPLANTATION (2012) (1)
- Immunotherapy in HCC—No rush despite the hype (2022) (1)
- Lessons from tips Peripheral arterial vasodilation is not the sole determinant of sodium retention in cirrhosis (1994) (1)
- Rhabdomyolysis after Intentional Acetaminophen and Carbon Monoxide Poisoning (2012) (1)
- Surgical Treatment and Radioembolization (2013) (1)
- CASE REPORT: Idiopathic Adulthood Ductopenia (2001) (1)
- Prognostic Factors for Effectiveness Outcomes After Transarterial Radioembolization in Metastatic Colorectal Cancer: Results From the Multicentre Observational Study CIRT. (2022) (1)
- Sorafenib (Sor) and mTOR inhibitors (mTORinh) combination for hepatocarcinoma recurrence after liver transplantation. (2011) (1)
- In reply to Dr. Kao et al. (2011) (1)
- Updated data from an ongoing study with ADP-A2AFP spear T-cells (2020) (1)
- The post-SIR-spheres surgery study (P4S): influence of prior chemotherapy on survival following hepatic resection in patients with metastatic colorectal cancer previously treated with selective internal radiation therapy (SIRT) (2016) (1)
- Analysis of the albumin‐bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct‐acting antiviral therapy (2022) (1)
- Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib (2022) (1)
- Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial (2022) (1)
- Locoregional Transarterial Therapies for Hepatocellular Carcinoma: Transarterial Chemoembolization and Radioembolization (2013) (1)
- Abstract 2354: Cancer vaccine development for hepatocellular carcinoma - HEPAVAC (2016) (1)
- Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. (2014) (1)
- 357 A potential therapy for liver metastasis mediated by the inducible expression of interleukin-12 (IL-12) using gutless adenoviral vector (2004) (1)
- DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis (2022) (1)
- Immunotherapy in hepatocellular carcinoma - No rush despite the hype. (2022) (1)
- Lymphocytes from Carcinoembryonic Antigen Identification of an Antigenic Epitope for Helper T Updated Version (2002) (1)
- Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study (2022) (1)
- In Vitro Model for Simulating Drug Delivery during Balloon-Occluded Transarterial Chemoembolization (2021) (1)
- Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease (2021) (1)
- 180 Results of a randomized double-blind, controlled pilot study of the administration of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis (2004) (1)
- TARE ought not to borrow future liver function from patients with HCC. But does it? (2023) (0)
- SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis (2019) (0)
- 1028 INCIDENCE AND RISK FACTORS OF RADIOEMBOLIZATION (RE)-INDUCED LIVER DISEASE: RESULTS OF GLOBAL THERAPEUTIC STRATEGY AIMING TO PREVENTION (2012) (0)
- Abstract 2361: Big data analysis allows the identification of long non-coding RNAs with therapeutic potential against hepatocellular carcinoma (2018) (0)
- Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease (2021) (0)
- Serum lipidomics as diagnostic potential for metabolic-associated hepatocellular carcinoma (2021) (0)
- Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. (2023) (0)
- [Gene therapy: what is it and what is its use?]. (2005) (0)
- Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma (2023) (0)
- From the Editor’s Desk… (2021) (0)
- 561 FACTORS PREDICTIVE OF TOLERANCE AFTER LIVER TRANSPLANTATION (2013) (0)
- Effective and safe gene therapy of experimental liver cancer by intratumoral injection of a defective adenovirus containing the thymidine kinase gene (1999) (0)
- From the Editor's Desk... (2023) (0)
- What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association (2022) (0)
- 157A comparison of tacrolimus and cyclosporine microemulsion as primary immunosuppressants after liver transplantation (2000) (0)
- [Gene therapy for liver diseases]. (2000) (0)
- Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial (2022) (0)
- Reply (2012) (0)
- From the Editor's Desk (1957) (0)
- 808. Monitoring of Transgene Expression in Cancer Patients with Positron Emission Tomography (PET) (2005) (0)
- From the Editor's Desk…. (2020) (0)
- 564 Spectrum of hepatobiliary disease in adults with heterozygous MDR3 deficiency (2004) (0)
- Contents (2020) (0)
- From the Editor's Desk... (2020) (0)
- Contents (2020) (0)
- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma (2017) (0)
- Subject Index Vol. 62, 2002 (2002) (0)
- Results in Liver Metastatic Colorectal Cancer (2013) (0)
- Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma (2017) (0)
- Complete Response under Sorafenib Treatment for Hepatocellular Carcinoma is Associated to Development of Dermatology Adverse Events (2016) (0)
- Pattern of progression determines post-progression survival in patients with hepatocellular carcinoma treated with Radioembolization (2018) (0)
- From the Editor's Desk... (2022) (0)
- From the Editor's Desk…. (2020) (0)
- Computational study of a novel catheter for liver radioembolization (2022) (0)
- From the Editor's Desk…. (2020) (0)
- From the Editor’s Desk… (2001) (0)
- Factors predicting survival after transjugular intrahepaticportosystemic shunt (TIPS) (2000) (0)
- Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
- O72 PHASE 1–2 CLINICAL TRIAL IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS TREATED WITH BONE-MARROW DERIVED ENDOTHELIAL PROGENITOR CELLS: PRELIMINARY SAFETY AND EFFICACY ANALYSIS (2014) (0)
- Early acute rejection after liver transplantation (LT): Multivariate analysis of risk factors (2000) (0)
- From the Editor's desk…. (2021) (0)
- Impact of prior procedures on overall survival following radioembolization in patients with unresectable hepatocellular carcinoma (HCC). (2011) (0)
- From the Editor's Desk... (2022) (0)
- Risk factors for metabolic complications after liver transplantation(LT). Multivariate logistic regression analysis (2000) (0)
- Subject Index Vol. 19, 2001 (2002) (0)
- From the Editor’s Desk… (2020) (0)
- [Antiemetic inefficacy of high intravenous doses of metoclopramide by short-term infusion in vomiting induced by antineoplastic chemotherapy]. (1986) (0)
- From the Editor's Desk... (2020) (0)
- Histopathologic study in transjugular intrahepatic portosystemic shunt (TIPS) (1998) (0)
- 412 ISOLATION AND DIFFERENTIATION OF BONE MARROW-DERIVED ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ADVANCED LIVER CIRRHOSIS FOR THERAPEUTICAL USE (2012) (0)
- EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma. (2023) (0)
- Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) (2023) (0)
- Radioembolization for unresectable hepatocellular carcinoma (HCC) in the elderly. (2011) (0)
- Combination immunotherapy for hepatocellular carcinoma. (2023) (0)
- Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis (2020) (0)
- From the Editor's Desk... (2022) (0)
- Cyclophosphamide for Metastatic Cancer Combined with GM-CSF, Pegylated IFN, and Loaded with Autologous Tumor Lysates Pilot Clinical Trial of Type 1 Dendritic Cells (2011) (0)
- New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming (2022) (0)
- From the Editor's Desk... (2022) (0)
- Abstract No. 201: Survival and tolerability following 90Y-resin microsphere radioembolization in patients with unresectable BCLC stage C hepatocellular carcinoma (HCC) (2012) (0)
- Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population (2020) (0)
- From the Editor's Desk... (2022) (0)
- Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. (2022) (0)
- PS-137-A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma (2019) (0)
- PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma (2019) (0)
- Contents Vol. 19, 2001 (2002) (0)
- From the Editor's Desk... (2023) (0)
- P0235 : Protein N-terminal acetylation inhibition as a novel therapeutic target for hepatocellular carcinoma (2015) (0)
- P552 PROTEOMIC ANALYSIS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER LIVER RADIOEMBOLIZATION. PRELIMINARY RESULTS (2014) (0)
- From the Editor's Desk… (2020) (0)
- Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals (2018) (0)
- Computational Study of the Microsphere Concentration in Blood during Radioembolization (2022) (0)
- Identification of neoantigens as potential vaccines in hepatocellular carcinoma (2020) (0)
- From the Editor's Desk…. (2021) (0)
- P966 EVALUATION OF THE PREVENTIVE EFFECT OF LOW DOSE ENOXAPARIN, PENTOXIFYLLINE AND URSODEOXYCHOLIC ACID TO RADIATION INDUCED LIVER TOXICITY IN A PROSPECTIVE RANDOMIZED TRIAL (2014) (0)
- Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. (2022) (0)
- 625. Viral Shedding after Intratumoral Injection of Adenoviral Vectors to Patients with Cancer (2006) (0)
- Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers (2023) (0)
- Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma (2021) (0)
- Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet (2020) (0)
- Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma (2022) (0)
- [Liver enzyme elevation secondary to macroenzymes: macro-GOT]. (2013) (0)
- Splenic embolization (SE) in the treatment of hypersplenism due to portal hypertension (HS-PHT) (1989) (0)
- Personalized Medicine and Imaging Serum Interleukin-8 Re fl ects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins (2014) (0)
- Conversion to mycophenolate mofetil (MMF) instead of cyclosporine a (CYA) in liver transplant (LT) recipients with renal function impairment. A pilot study (1998) (0)
- 375 LIVER RADIOEMBOLIZATION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY AND ANTITUMOR EFFECT (2008) (0)
- From the Editor's Desk…. (2022) (0)
- Nivolumab Versus Sorafenib Treatment in Advanced Hepatocellular Carcinoma (CheckMate 459): A Randomised, Multicentre, Open-Label, Phase 3 Trial (2021) (0)
- FRI-462-A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis (2019) (0)
- Abstract 1059: Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model (2017) (0)
- Tips for portal hypertension in liver cirrhosis technic and early clinical experience utility in a liver transplantation program (1992) (0)
- Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study (2022) (0)
- From the Editor's Desk... (2023) (0)
- Case Report: Effectiveness of Lamivudine in Treatment of Acute Recurrent Hepatitis B After Liver Transplantation (1998) (0)
- RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC). (2023) (0)
- Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial (2023) (0)
- Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (2023) (0)
- Cancer gene therapy: the experience from clinical trials (2007) (0)
- From the Editor's Desk... (2022) (0)
- From the Editor's Desk…. (2020) (0)
- Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression (2022) (0)
- From the Editor's Desk... (2021) (0)
- Regresión tumoral espontánea. A propósito de dos casos (1990) (0)
- SAT-454-Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC) (2019) (0)
- Contents (2020) (0)
- From the Editor's Desk... (2020) (0)
- Performance of the Hap Score among Patients with Hepatocellular Carcinoma Treated by Radioembolization (2016) (0)
- 260 Risks and benefit of diagnostic of biopsy of liver lesions before liver transplantation (2006) (0)
- Impact of early acute rejection (EAR) on outcome after liver transplantation (LT) (2000) (0)
- From the Editor's Desk… (2020) (0)
- 141 Results of liver transplantation in patients with hepatocellular carcinoma. Milan versus expanded criteria (2006) (0)
- Abstract No. 200: Evaluation of safety, tolerability and overall survival following whole-liver, lobar or segmental radioembolization in unresectable hepatocellular carcinoma (HCC) (2012) (0)
- Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis (2022) (0)
- Contents Vol. 62, 2002 (2002) (0)
- Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. (2023) (0)
- From the Editor's Desk... (2023) (0)
- How Could 90Y-Loaded Microsphere Distribution Be Optimized? (2022) (0)
- O052 : Assessment of the hong kong liver cancer staging system in europe (2015) (0)
- P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study (2021) (0)
- 928 Insulin-like growth factor-I (IGF-I) therapy in patients with advanced liver cirrhosis. Results of a randomized double-blind, controlled pilot study (2003) (0)
- From the Editor’s Desk… (2022) (0)
- Abstract IA25: Targeted therapies for hepatocellular carcinoma (2017) (0)
- Serum interleukin-8 and its relationship to tumor burden and treatment response across malignancies of multiple tissue origins. (2014) (0)
- Contents, Vol. 25, 1995 (1995) (0)
- Positron emission tomography (PET) imaging of AdCMVTk biodistributionin ortothopic hepatocellular carcinoma gene therapy (2002) (0)
- From the Editor’s Desk… (2001) (0)
- 1056 COMPARISON OF TWO DIFFERENT PROBES FOR TRANSIENT ELASTOGRAPHY FOR THE EVALUATION OF LIVER STIFFNESS (2012) (0)
- From the Editor's Desk... (2021) (0)
- Minimally invasive liver surgery for hepatocellular carcinoma in patients with portal hypertension (2023) (0)
- Engineering tumor specific replicating adenovirus as therapeutic agent for treatment of hepatocellular carcinoma (HCC) (2003) (0)
- P-17 Real-life use and long-term effectiveness results from CIREL – the multi-centre, observational study on irinotecan-eluting transarterial chemoembolization in CRLM (2022) (0)
- Abstract A043: Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant®): HEPAVAC (2016) (0)
- Reply to: "Toxicity and dosimetry in SORAMIC study": Y90 radioembolization is less about tumor dose, but preserving liver function: SIRT should mimic selective techniques as employed in TACE. (2020) (0)
- From the Editor's Desk... (2022) (0)
- Abstract A115: Cancer vaccine development for hepatocellular carcinoma – HEPAVAC (2016) (0)
- Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884]. (2020) (0)
- Selective internal radiation therapy (SIRT) of inoperable primary and metastatic hepatic tumors with 90-Yttrium microspheres (SIR-Spheres(R)) (2006) (0)
- From the Editor's Desk... (2021) (0)
- DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis (2022) (0)
- Downstaging to liver resection by radioembolization: a difficult to reach strategy? Author reply. (2013) (0)
- From the Editor's Desk…. (2020) (0)
- Assesment of extrahepatic dissemination (EHD)among patients with hepatocellular carcinoma (HCC) and long survival after treatment (1991) (0)
- Dual inhibition of DNA methyltransferase 1 and the histone methyltransferase G9a as a new therapeutic strategy in hepatoblastoma (2020) (0)
- THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins (2019) (0)
- Tu1483 - Hepatic Safety and Biomarker Assessments in Sorafenibexperienced Patients with Advanced Hepatocellular Carcinoma Treated with Nivolumab in the Checkmate-040 Study (2018) (0)
- Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study (Preprint) (2019) (0)
- Contents (2020) (0)
- From the Editor's Desk... (2021) (0)
- Novel role of amphiregulin in bile acids metabolism and protection from cholestatic liver injury (2018) (0)
- From the Editor's Desk... (2021) (0)
- Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma (2020) (0)
- The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development (2022) (0)
- Yttrium-90 PET/CT for the assessment of post-treatment microspheres biodistribution (2013) (0)
- From the Editor's Desk…. (2021) (0)
- From the Editor's Desk... (2022) (0)
- Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma (2013) (0)
- Survival After Intra-Arterial Treatment for Hepatocellular Carcinoma: Impact of Liver Dysfunction and Development of a Predictive Statistical Model: an International Collaborative Project (2015) (0)
- Description of a novel MDR3 gene mutation causing juvenil cholelithiasis, cholelithiasis of pregnancy and adulthood biliary cirrhosis. A family study (2003) (0)
- Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial (2022) (0)
- hepatic vein involvement in hepatocellular carcinoma : its disappearance with intra-arterial chemotherapy (1991) (0)
- 252PSERUM INTERLEUKIN-8 REFLECTS TUMOR BURDEN AND TREATMENT RESPONSE ACROSS MALIGNANCIES OF MULTIPLE TISSUE ORIGINS. (2014) (0)
- Subject Index Vol. 25, 1995 (1995) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Bruno Sangro?
Bruno Sangro is affiliated with the following schools: